=== CHUNK 1 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 2', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
local title: approval of promotional and non-promotional materials 
concerning products iberia cluster
1
objective
the objective of this document is to describe the process of managing promotional and 
nonpromotional content, developed by grünenthal spain and grünenthal portugal 
(cluster iberia) for external, as well as internal communication, independent of media 
type and channel used. the process for the recall of all promotional and non-
promotional materials is also described
2
scope
this document applies to all iberia cluster employees involved in the design, review,
approval and distribution and recall of materials, as well as their submission to the
autonomous community of madrid (cam) or infarmed (portuguese authority for
medicines).
the following activities are included in the scope:

developing content

reviewing and approving content on cluster level

maintaining content
in scope of this this proc are the following materials:

promotional materials
-
concerning medicinal products for human use,
-
concerning non-product related training,
-
concerning medical devices used to administer medication.

non-promotional materials of a scientific nature.

branded and unbranded press releases

online content created and/or disseminated by grünenthal in the iberia 
cluster, independently of the channel used to disseminate the material (face-
to-face, web based, social media (for non-branded materials only, etc.).
out of the scope of this procedure are materials related to market research studies as
described in proc-003193 gsop_develop content for primary market researches 
and risk management plans and related materials due to the fact that these ones are 
regulated according to the pharmacovigilance applicable regulations. also, any official 
documents prepared and used for the pricing and reimbursement process (e.g. core 
value dossier) are not included in this process due to being officially required 
documents and for a nonpromotional use.

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 2.
Local Title: APPROVAL OF PROMOTIONAL AND NON-PROMOTIONAL MATERIALS 
CONCERNING PRODUCTS IBERIA CLUSTER
1
OBJECTIVE
The objective of this document is to describe the process of managing promotional and 
nonpromotional content, developed by Grünenthal Spain and Grünenthal Portugal 
(Cluster Iberia) for external, as well as internal communication, independent of media 
type and channel used. The process for the recall of all promotional and non-
promotional materials is also described
2
SCOPE
This document applies to all Iberia Cluster employees involved in the design, review,
approval and distribution and recall of materials, as well as their submission to the
Autonomous Community of Madrid (CAM) or INFARMED (Portuguese Authority for
Medicines).
The following activities are included in the scope:

Developing content

Reviewing and approving content on cluster level

Maintaining content
In scope of this this PROC are the following materials:

Promotional materials
-
concerning medicinal products for human use,
-
concerning non-product related training,
-
concerning medical devices used to administer medication.

Non-promotional materials of a scientific nature.

Branded and unbranded press releases

Online content created and/or disseminated by Grünenthal in the Iberia 
Cluster, independently of the channel used to disseminate the material (face-
to-face, web based, social media (for non-branded materials only, etc.).
Out of the scope of this procedure are materials related to market research studies as
described in PROC-003193 GSOP_Develop content for Primary Market Researches 
and Risk Management Plans and related materials due to the fact that these ones are 
regulated according to the pharmacovigilance applicable regulations. Also, any official 
documents prepared and used for the Pricing and Reimbursement process (e.g. Core 
Value Dossier) are not included In this process due to being officially required 
documents and for a nonpromotional use.

==================================================

=== CHUNK 2 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 3', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
the employees involved have a duty to be aware of all legislation and regulations 
applicable to the advertising and promotion of medicines and to comply with these in 
their day-to-day work
3
responsibilities
this section provides information on the functions involved in the process described
function/role
responsibility
medical affairs
asset lead
brand manager
product manager
omnichannel manager
market access specialist
communication and patient
specialist
when acting as sponsor of the material, 
prepare the material and ensure
compliance with the applicable
regulations.
if necessary, adapt ghq materials to 
local needs and regulations, thus 
ensuring compliance with the applicable 
regulations.
ensure that all materials are modified in 
accordance with the comments and 
observations received, thus ensuring 
compliance with the applicable 
regulations.
prepare the material in the review tool to 
initiate the review process that applies 
to each material.
prepare the material for a paper-based 
review by the parties involved if the 
review tool is not functioning  correctly 
or if review via the tool is not applicable.
make the changes requested by the 
different departments in the review
process.
activate production once the final 
version of the material has been
accepted and signed, with all approved 
changes.
prepare the documentation for 
submission to cam/ infarmed.
ensure that the material is destroyed 
when it becomes obsolete or has been 
subject to a review/ recall, informing the 
ds team if it was safety-related and the 
compliance with the timelines required 
by category.
medical affairs
(manager/msl/advisor)
in materials prepared by ghq, make 
the appropriate adaptations, thus 
guaranteeing compliance with the
applicable regulations.

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 3.
The employees involved have a duty to be aware of all legislation and regulations 
applicable to the advertising and promotion of medicines and to comply with these in 
their day-to-day work
3
RESPONSIBILITIES
This section provides information on the functions involved in the process described
Function/Role
Responsibility
Medical Affairs
Asset Lead
Brand Manager
Product Manager
Omnichannel Manager
Market Access Specialist
Communication and Patient
Specialist
When acting as sponsor of the material, 
prepare the material and ensure
compliance with the applicable
regulations.
If necessary, adapt GHQ materials to 
local needs and regulations, thus 
ensuring compliance with the applicable 
regulations.
Ensure that all materials are modified in 
accordance with the comments and 
observations received, thus ensuring 
compliance with the applicable 
regulations.
Prepare the material in the review tool to 
initiate the review process that applies 
to each material.
Prepare the material for a paper-based 
review by the parties involved if the 
review tool is not functioning  correctly 
or if review via the tool is not applicable.
Make the changes requested by the 
different departments in the review
process.
Activate production once the final 
version of the material has been
accepted and signed, with all approved 
changes.
Prepare the documentation for 
submission to CAM/ INFARMED.
Ensure that the material is destroyed 
when it becomes obsolete or has been 
subject to a review/ recall, informing the 
DS team if it was safety-related and the 
compliance with the timelines required 
by category.
Medical Affairs
(Manager/MSL/Advisor)
In materials prepared by GHQ, make 
the appropriate adaptations, thus 
guaranteeing compliance with the
applicable regulations.

==================================================

=== CHUNK 3 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 4', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
in materials proposed by the brand 
manager, product manager asset lead, 
omnichannel manager, market access 
specialist or communication and 
patient specialist, review the scientific 
content.
ensure scientific accuracy and 
robustness of claims and data against 
relevant product information,
available data on file or published 
references.
validity of references (the most up to 
date), copyrights and suitability of 
graphics and pictures against label.
country regulatory affairs
manager
check against the relevant product 
information texts (“label”) and local rules 
for promotion and advertising
of medicinal products.
medical information manager
review bibliographic references for final 
approval.
qp/ technical responsible for
the corresponding mah
review materials with information and 
messages intended for advertising and 
promoting medical devices used to 
administer medication.
drug safety lrppv/ deputy
check that material safety messages 
are properly included in accordance with 
the product information and pv 
regulations. review all non-promotional
material to follow the applicable 
pharmacovigilance processes.
compliance officer / local
compliance liaison/legal
check that the material complies with 
the applicable regulations for approval, 
with comments and signature. sanity 
check of the following areas:
unfair competition laws, medical 
advertising laws, product- and civil-
liability, correctness of corporate
information. 
check against the global compliance 
framework, with focus on ethical
behaviour towards patients,hcps, 
payers, authorities and other relevant
stakeholders as well as grünenthal’s 
ethical perception in the current context

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 4.
In materials proposed by the Brand 
Manager, Product Manager Asset Lead, 
Omnichannel Manager, Market Access 
Specialist or Communication and 
Patient Specialist, review the scientific 
content.
Ensure scientific accuracy and 
robustness of claims and data against 
relevant product information,
available data on file or published 
references.
Validity of references (the most up to 
date), copyrights and suitability of 
graphics and pictures against label.
Country Regulatory Affairs
Manager
Check against the relevant product 
information texts (“label”) and local rules 
for promotion and advertising
of medicinal products.
Medical Information Manager
Review bibliographic references for final 
approval.
QP/ Technical Responsible for
the corresponding MAH
Review materials with information and 
messages intended for advertising and 
promoting medical devices used to 
administer medication.
Drug Safety LRPPV/ Deputy
Check that material safety messages 
are properly included in accordance with 
the product information and PV 
regulations. Review all non-promotional
material to follow the applicable 
pharmacovigilance processes.
Compliance Officer / Local
Compliance Liaison/Legal
Check that the material complies with 
the applicable regulations for approval, 
with comments and signature. Sanity 
check of the following areas:
Unfair competition laws, medical 
advertising laws, product- and civil-
liability, correctness of corporate
Information. 
Check against the Global Compliance 
Framework, with focus on ethical
behaviour towards patients,HCPs, 
payers, authorities and other relevant
stakeholders as well as Grünenthal’s 
ethical perception in the current context

==================================================

=== CHUNK 4 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 5', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
and environment and ensure
compliance with applicable regulations.
asset lead / brand manager
product manager
omnichannel manager
market access specialist
communication specialist
check content alignment with source 
data, check the accuracy of figures, 
numbers and diagrams, etc., and check 
the correctness of any claim.
head medical affairs
check that the content of the material 
complies with the applicable regulations, 
with comments and signature.
head of marketing
check that the messages and content 
are correct and in line with the strategy 
(both local materials and adapted ghq 
materials) and that they comply with the 
applicable regulations, with comments 
and signature.
head of market access & pricing
check that the messages and content 
are correct and in line with the strategy 
(both local materials and adapted ghq 
materials) and that they comply with the 
applicable regulations, with comments 
and signature.
legal and compliance
submit the approved materials to cam / 
infarmed and upload proof of
submission to the tool.
4
terms and definitions
term
definition
company
grünenthal cluster iberia
veevapromomats
grünenthal´s content management system (cms)
non-promotional content
non brand -related educational content e.g.; disease-
related content, advisory board, press releases on 
milestones regarding research & development, 
independent press reports about symposia and
statements by scientists (even if
organized by grünenthal).
promotional content
any activity or inducement designed to promote the 
prescription, supply, sale, or consumption of a specific 
pharmaceutical product.
module
a combination of claims, general text and digital assets 
(images, logos,…) used to convey a message

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 5.
and environment and ensure
compliance with applicable regulations.
Asset Lead / Brand Manager
Product Manager
Omnichannel Manager
Market Access Specialist
Communication Specialist
Check content alignment with source 
data, check the accuracy of figures, 
numbers and diagrams, etc., and check 
the correctness of any claim.
Head Medical Affairs
Check that the content of the material 
complies with the applicable regulations, 
with comments and signature.
Head of Marketing
Check that the messages and content 
are correct and in line with the strategy 
(both local materials and adapted GHQ 
materials) and that they comply with the 
applicable regulations, with comments 
and signature.
Head of Market Access & Pricing
Check that the messages and content 
are correct and in line with the strategy 
(both local materials and adapted GHQ 
materials) and that they comply with the 
applicable regulations, with comments 
and signature.
Legal and Compliance
Submit the approved materials to CAM / 
Infarmed and upload proof of
submission to the tool.
4
TERMS AND DEFINITIONS
Term
Definition
Company
Grünenthal Cluster Iberia
VeevaPromoMats
Grünenthal´s Content Management System (CMS)
Non-promotional content
Non brand -related educational content e.g.; disease-
related content, advisory board, press releases on 
milestones regarding research & development, 
Independent press reports about symposia and
statements by scientists (even if
organized by Grünenthal).
Promotional content
Any activity or inducement designed to promote the 
prescription, supply, sale, or consumption of a specific 
pharmaceutical product.
Module
A combination of claims, general text and digital assets 
(images, logos,…) used to convey a message

==================================================

=== CHUNK 5 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 7', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
review/approval for our material related to the new content creation process in addition 
to the standard process of review/approval of promotional and non-promotional
materials.
5.1
electronic review and approval workflow
a) promotional materials initiated by ghq departments.
the procedure set out in proc-002054 must be followed: manage promotional and
non-promotional content.
b) materials initiated by local departments:
this requires approval of all roles involved in the approval procedure.
applies to all other materials.
opioid-related materials that are not in line with the key documents corresponding to 
the global opioid product strategy approved by the company (product plan, brand book, 
value dossier, etc.), such as promotional campaigns, digital campaigns, medical 
initiatives, etc., must be referred to the rou-b for evaluation in accordance with 
proc-007055 - communication on opioids in portugal and proc-007115 in spain.
in the case of non-promotional materials, notification to cam/infarmed is not
necessary.
5.2
electronic approval procedure
the process consists of the following stages:
5.2.1
creation of the material:
creation of the material
assigned role
responsibility
status
sponsor
1 - define the material jointly with the other roles involved in 
each case before submitting it to the review cycle for approval.
development of the content
upload of the draft material in veeva promomats
na
the roles involved in each material are responsible for ensuring that the material 
complies with the applicable regulations.

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 7.
review/approval for our material related to the new content creation process in addition 
to the standard process of review/approval of promotional and non-promotional
materials.
5.1
Electronic review and approval workflow
a) Promotional materials initiated by GHQ departments.
The procedure set out in PROC-002054 must be followed: Manage promotional and
non-promotional content.
b) Materials initiated by local departments:
This requires approval of all roles involved in the approval procedure.
Applies to all other materials.
Opioid-related materials that are not in line with the key documents corresponding to 
the global opioid product strategy approved by the company (product plan, brand book, 
value dossier, etc.), such as promotional campaigns, digital campaigns, medical 
initiatives, etc., must be referred to the ROU-B for evaluation in accordance with 
PROC-007055 - Communication on opioids in Portugal and PROC-007115 in Spain.
In the case of non-promotional materials, notification to CAM/INFARMED is not
necessary.
5.2
Electronic approval procedure
The process consists of the following stages:
5.2.1
Creation of the material:
Creation of the material
Assigned role
Responsibility
Status
Sponsor
1 - Define the material jointly with the other roles involved in 
each case before submitting it to the review cycle for approval.
Development of the content
Upload of the draft material in Veeva PromoMats
NA
The roles involved in each material are responsible for ensuring that the material 
complies with the applicable regulations.

==================================================

=== CHUNK 6 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 8', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
5.2.2
uploading the material to the tool:
the tool, veevapromomats, holds the documentation necessary to verify the accuracy 
of the information on the material (articles, photocopies from journals, referenced 
books, etc.).
each time the review workflow moves forward, the tool users involved in each material 
will receive an automatic email notifying them of the task to be performed.
within the tool itself, the tasks assigned to each user can be seen in “my tasks” and 
the notifications in the “notifications” section.
uploading the material to the tool
assigned role
responsibility
status
sponsor
upload the material to the tool, along with the smpc, and 
bibliographic references, as applicable.
name the material so that it is identifiable. minimum 
information required: - "name" “subclassification”,
“audience”, “promotional/non-
promotional”, “internal/external”,“channel”, “version” 
”language” ,
• "country"
• “product”
enter the references related to the material in the “supporting 
documents” section, highlighting the text that supports the 
promotional message.
use “links” and “anchors” to associate posts with the part(s) of 
the post(s) that support each message.
draft
the reduced smpc, or the qr code that links to the updated reduced smpc
for the product, must form part of the promotional material and not solely be
included in the “supporting documents” section.
5.2.3
reviewing the material in the tool:
reviewing the material in the tool
material initiated by one of the following departments: marketing, commercial 
excellence, communications, medical affairs, market access, governmental affairs, 
regulatory affairs, legal, drug safety, compliance and finance
role
responsibility
status
sponsor
start the material review process through the tool by sending 
the corresponding “start review” task to medical affairs.
in review
medical affairs indicate the necessary modifications (if any) using annotations 
(“annotate”).
review 
complete
material initiated by the medical department

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 8.
5.2.2
Uploading the material to the tool:
The tool, VeevaPromoMats, holds the documentation necessary to verify the accuracy 
of the information on the material (articles, photocopies from journals, referenced 
books, etc.).
Each time the review workflow moves forward, the tool users involved in each material 
will receive an automatic email notifying them of the task to be performed.
Within the tool itself, the tasks assigned to each user can be seen in “My tasks” and 
the notifications in the “Notifications” section.
Uploading the material to the tool
Assigned role
Responsibility
Status
Sponsor
Upload the material to the tool, along with the SmPC, and 
bibliographic references, as applicable.
Name the material so that it is identifiable. Minimum 
information required: - "Name" “subclassification”,
“Audience”, “Promotional/Non-
Promotional”, “Internal/External”,“Channel”, “Version” 
”language” ,
• "Country"
• “Product”
Enter the references related to the material in the “Supporting 
Documents” section, highlighting the text that supports the 
promotional message.
Use “links” and “anchors” to associate posts with the part(s) of 
the post(s) that support each message.
Draft
The reduced SmPC, or the QR code that links to the updated reduced SmPC
for the product, must form part of the promotional material and not solely be
included in the “Supporting Documents” section.
5.2.3
Reviewing the material in the tool:
Reviewing the material in the tool
Material initiated by one of the following departments: Marketing, Commercial 
Excellence, Communications, Medical Affairs, Market Access, Governmental Affairs, 
Regulatory Affairs, Legal, Drug Safety, Compliance and Finance
Role
Responsibility
Status
Sponsor
Start the material review process through the tool by sending 
the corresponding “Start review” task to Medical Affairs.
In review
Medical Affairs Indicate the necessary modifications (if any) using annotations 
(“Annotate”).
Review 
complete
Material initiated by the Medical Department

==================================================

=== CHUNK 7 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 9', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
sponsor
start the material review process through the tool by sending 
the corresponding “start review” task to the medical affairs.
in review
medical affairs indicate the necessary modifications (if any) using annotations 
(“annotate”).
review 
complete
5.2.4
approval by the roles or departments involved:
once the review is complete, the process continues as follows:
parallel approval of the material in the tool
assigned role
responsibility
status
sponsor
initiate the "start approval” circuit by distributing the 
material in parallel to the other roles and departments 
involved in the review process according to the matrix 
below
manually enter the number of days the reviewers have to 
complete their task, always in working days and with a 
minimum of 72 hours from the moment the material is sent 
for review by each role, or in accordance with the matrix 
below.
in 
approval
roles that review according to the material type:
materials
minimum approvers
minimum certifiers
target timelines
target timeframe 
for approvers and 
certifiers to 
complete tasks
(or according with 
request of the 
originator)
asset plan
medical
compliance
marketing
country 
manager
approval: 5 working 
days
certification: 5 
working days
action plan (pda)
medical
marketing
medical affairs
approval: 3 working 
days
certification: n/a

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 9.
Sponsor
Start the material review process through the tool by sending 
the corresponding “Start review” task to the Medical Affairs.
In review
Medical Affairs Indicate the necessary modifications (if any) using annotations 
(“Annotate”).
Review 
complete
5.2.4
Approval by the roles or departments involved:
Once the review is complete, the process continues as follows:
Parallel approval of the material in the tool
Assigned role
Responsibility
Status
Sponsor
Initiate the "Start approval” circuit by distributing the 
material in parallel to the other roles and departments 
involved in the review process according to the matrix 
below
Manually enter the number of days the reviewers have to 
complete their task, always in working days and with a 
minimum of 72 hours from the moment the material is sent 
for review by each role, or in accordance with the matrix 
below.
In 
approval
Roles that review according to the material type:
Materials
Minimum Approvers
Minimum Certifiers
Target Timelines
Target timeframe 
for approvers and 
certifiers to 
complete tasks
(or according with 
request of the 
originator)
Asset plan
Medical
Compliance
Marketing
Country 
Manager
Approval: 5 working 
days
Certification: 5 
working days
Action plan (PDA)
Medical
Marketing
Medical Affairs
Approval: 3 working 
days
Certification: n/a

==================================================

=== CHUNK 8 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 10', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
leave behind, detail 
aid,, (approved) e-
mail, invitation, 
agenda, core claims 
document, banner, 
booth, , grt website
ra/drug safety
marketing / market 
access/communication
medical
compliance
medical information
medical affairs
approval: 3 working 
days certification: 3 
working days
medical product 
training, pain 
external/disease 
training external
ra/drug safety
medical
compliance
medical information
medical affairs
approval: 3 working 
days certification: 3 
working days
medical training, 
advisory board 
materials, webinar, 
invitation, agenda,
ra/drug safety (pt)
medical
compliance
market access
medical affairs
approval: 3 working 
days certification: 3 
working days
local poster, 
manuscript
ra/drug safety
medical
global medical
market access
ra (pt)/
compliance (es) 
and 
pharmacovigilance 
(es)
medical

global medical if 
applicable 
according to
proc-004064
approval: 5 working 
days (global 15)
certification: 5 
working
days (global 3)
speaker slides (ref 
not anchored)
ra/drug safety (pt)
medical
compliance
ra (pt),
compliance (es)
medical affairs
approval: 1 working 
days certification: 1 
working days
training
marketing
medical
medical affairs
approval: 3 working 
days certification: 3 
working days
press release related 
to opioids
medical
compliance
communication
roub team
medical information
medical affairs
approval: 2 working 
days
certification: 2 
working days

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 10.
Leave behind, detail 
aid,, (approved) e-
mail, invitation, 
agenda, core claims 
document, banner, 
booth, , GRT website
RA/Drug Safety
Marketing / Market 
Access/Communication
Medical
Compliance
Medical Information
Medical Affairs
Approval: 3 working 
days Certification: 3 
working days
Medical product 
training, pain 
external/disease 
training external
RA/Drug Safety
Medical
Compliance
Medical Information
Medical Affairs
Approval: 3 working 
days Certification: 3 
working days
Medical training, 
advisory board 
materials, webinar, 
invitation, agenda,
RA/Drug Safety (PT)
Medical
Compliance
Market Access
Medical Affairs
Approval: 3 working 
days Certification: 3 
working days
Local poster, 
manuscript
RA/Drug safety
Medical
Global medical
Market Access
RA (PT)/
Compliance (ES) 
and 
Pharmacovigilance 
(ES)
Medical

Global medical if 
applicable 
according to
PROC-004064
Approval: 5 working 
days (global 15)
Certification: 5 
working
days (global 3)
Speaker slides (ref 
not anchored)
RA/Drug Safety (PT)
Medical
Compliance
RA (PT),
Compliance (ES)
Medical Affairs
Approval: 1 working 
days Certification: 1 
working days
Training
Marketing
Medical
Medical Affairs
Approval: 3 working 
days Certification: 3 
working days
Press release related 
to opioids
Medical
Compliance
Communication
ROUB Team
Medical information
Medical Affairs
Approval: 2 working 
days
Certification: 2 
working days

==================================================

=== CHUNK 9 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 11', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
social media (eg 
linkedin, twitter etc.)
medical
compliance
communication
medical affairs
approval: 3 working 
days certification: 3 
working days
pt abbreviated (mpc
ra
drug safety
marketing
medical
compliance
ra
drug safety
head of medical 
affairs
approval: 3 working 
days certification: 3 
working days
press releases not opioid related are approved by email by medical and compliance,
dsmn8 and all the content for rrss are also approved by email by mkt , corporate
communication, omnichannel medical and compliance.
all people with functions involved in this procedure should make the comments or
observations they deem appropriate and choose one of these possible material
classifications:
a) “approved” if no changes are required;
b) “approved with changes” if any changes are necessary;
c) “amend and resubmit” if it is considered necessary to restart the workflow 
from the beginning (i.e. “draft” status).
the review period must not exceed three working days per function involved, except 
in justified cases, in which case the period may be extended by a further two working 
days.
for press releases, the review period must not exceed one working day.
once the parallel review is complete, each role will sign the corresponding box in the 
tool electronically.
5.2.5
adaptation and final certification:
adaptation and certification of the material in the tool
assigned role responsibility
status
sponsor
enter comments or observations in a corrected version of 
the material through the “new version” option in the tool.
send the corrected material (final version) to the final 
approver through the “start final certification” option.
in certification
medical 
affairs
certify the validity of the material, provided that the corrected 
version of the material complies with the provisions of the 
applicable regulations.
approved for 
production

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 11.
Social media (eg 
LinkedIn, twitter etc.)
Medical
Compliance
Communication
Medical Affairs
Approval: 3 working 
days Certification: 3 
working days
PT abbreviated (mPC
RA
Drug Safety
Marketing
Medical
Compliance
RA
Drug Safety
Head of Medical 
Affairs
Approval: 3 working 
days Certification: 3 
working days
Press releases not opioid related are approved by email by Medical and compliance,
DSMN8 and all the content for RRSS are also approved by email by MKT , Corporate
Communication, Omnichannel Medical and Compliance.
All people with functions involved in this procedure should make the comments or
observations they deem appropriate and choose one of these possible material
classifications:
a) “approved” if no changes are required;
b) “approved with changes” if any changes are necessary;
c) “amend and resubmit” if it is considered necessary to restart the workflow 
from the beginning (i.e. “draft” status).
The review period must not exceed three working days per function involved, except 
in justified cases, in which case the period may be extended by a further two working 
days.
For press releases, the review period must not exceed one working day.
Once the parallel review is complete, each role will sign the corresponding box in the 
tool electronically.
5.2.5
Adaptation and final certification:
Adaptation and certification of the material in the tool
Assigned role Responsibility
Status
Sponsor
Enter comments or observations in a corrected version of 
the material through the “new version” option in the tool.
Send the corrected material (final version) to the final 
approver through the “start final certification” option.
In certification
Medical 
affairs
Certify the validity of the material, provided that the corrected 
version of the material complies with the provisions of the 
applicable regulations.
Approved for 
production

==================================================

=== CHUNK 10 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 12', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
the sponsor of the material will be automatically notified of the final certification 
through the tool and by an automatic email.
5.2.6
submission of materials to cam:
promotional materials will be submitted to cam in accordance with the applicable
regulations.
submission of materials to cam
assigned role
responsibility
status
spain
sponsor
in the “renditions” tab, upload the signed documents 
needed to submit the material to cam, in accordance 
with the applicable regulations:
a) approved promotional material (“viewable 
rendition”)
b) advertising communication for medicinal 
products for human use form in editable format, 
completed and signed electronically.
c) copy of the material in pdf.
d) copy of the drug authorization granted by 
aemps.
through the tool, send the final version of the material 
and the above-mentioned documents to the head of 
communication with cam.
approved for 
production
compliance/ 
legal
send the scientific service report to the drug 
advertising control division of the cam department of 
health by electronic means.
include the following with the report:
a) advertising communication for medicinal 
products for human use form.
b) copy of authorized ds or, failing that, of the 
authorized package leaflet.
c) copy of the material in pdf.
d) copy of the drug authorization granted by 
aemps.
attach proof of submission to cam (“submission
proof”) in the “attachments” tab of the tool.
approved for 
distribution

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 12.
The sponsor of the material will be automatically notified of the final certification 
through the tool and by an automatic email.
5.2.6
Submission of materials to CAM:
Promotional materials will be submitted to CAM in accordance with the applicable
regulations.
Submission of materials to CAM
Assigned role
Responsibility
Status
SPAIN
Sponsor
In the “Renditions” tab, upload the signed documents 
needed to submit the material to CAM, in accordance 
with the applicable regulations:
a) Approved promotional material (“viewable 
rendition”)
b) Advertising communication for medicinal 
products for human use form in editable format, 
completed and signed electronically.
c) Copy of the material in PDF.
d) Copy of the drug authorization granted by 
AEMPS.
Through the tool, send the final version of the material 
and the above-mentioned documents to the Head of 
Communication with CAM.
Approved for 
production
Compliance/ 
Legal
Send the Scientific Service Report to the Drug 
Advertising Control Division of the CAM Department of 
Health by electronic means.
Include the following with the report:
a) Advertising communication for medicinal 
products for human use form.
b) Copy of authorized DS or, failing that, of the 
authorized package leaflet.
c) Copy of the material in PDF.
d) Copy of the drug authorization granted by 
AEMPS.
Attach proof of submission to CAM (“submission
proof”) in the “Attachments” tab of the tool.
Approved for 
distribution

==================================================

=== CHUNK 11 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 13', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
due to restrictions on cam’s platform, the documents must comply with the technical 
specifications in force at the time the material is communicated.
submission of materials to infarmed
assigned role responsibility
status
portugal
sponsor
responsible for conducting the follow-up required to ensure 
all approval steps of the promotional material are completed 
in the veeva vault system, and to provide to the local 
compliance liaison the material to be submitted to 
infarmed – always before its distribution – or, where 
applicable, to inform the departments implicated in the 
approval that the material will not be distributed.
approved for 
distribution
lcl
submission of the promotional materials in the infarmed’s 
database in the legal timelines, and the archive of those 
materials, namely of the approval and certification folder, a 
copy of the material and the audit trail document, generated 
by the veeva vault system, for future possible inspections 
and audits.
sponsor
is responsible for assuring that two original copy of each 
authorized promotional material (final version) is made 
available to lcl for archiving.
is responsible recalling any expired material (though a 
dedicated email to involved business areas) for applying for 
the destruction of the promotional material when considered 
no longer appropriate for promotion. the destruction of the 
material will be requested directly by the sponsor through 
the web platform of the promotional logistic company. 
procurement will supervise the destruction of the material in 
due time and will receive an email with the confirmation of 
destruction.
lcl
in the case the mah of product is a third party, but marketed 
or promoted by grt-pt, the process follows the same steps 
with the exception of the notification of the material to 
infarmed which is performed by the mah. the lcl will 
send an email with all the necessary data to the mah to 
perform the submission
lcl will archive for a period of 5 years all the authorized 
promotional materials (final version- two specimens) 
together with a copy of the review and approval folder and 
the copies of the forms and scientific reports sent to 
infarmed for possible future inspections and audits

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 13.
Due to restrictions on CAM’s platform, the documents must comply with the technical 
specifications in force at the time the material is communicated.
Submission of materials to INFARMED
Assigned role Responsibility
Status
PORTUGAL
Sponsor
Responsible for conducting the follow-up required to ensure 
all approval steps of the Promotional Material are completed 
in the Veeva Vault system, and to provide to the Local 
Compliance Liaison the material to be submitted to 
INFARMED – always before its distribution – or, where 
applicable, to inform the departments implicated in the 
approval that the material will not be distributed.
Approved for 
distribution
LCL
Submission of the promotional materials in the INFARMED’s 
database in the legal timelines, and the archive of those 
materials, namely of the approval and certification folder, a 
copy of the material and the Audit Trail document, generated 
by the Veeva Vault system, for future possible inspections 
and audits.
Sponsor
Is responsible for assuring that two original copy of each 
authorized promotional material (final version) is made 
available to LCL for archiving.
Is responsible recalling any expired material (though a 
dedicated email to involved business areas) for applying for 
the destruction of the promotional material when considered 
no longer appropriate for promotion. The destruction of the 
material will be requested directly by the sponsor through 
the web platform of the promotional logistic company. 
Procurement will supervise the destruction of the material in 
due time and will receive an email with the confirmation of 
destruction.
LCL
In the case the MAH of product is a third party, but marketed 
or promoted by GRT-PT, the process follows the same steps 
with the exception of the notification of the material to 
INFARMED which is performed by the MAH. The LCL will 
send an email with all the necessary data to the MAH to 
perform the submission
LCL will archive for a period of 5 years all the authorized 
promotional materials (final version- two specimens) 
together with a copy of the review and approval folder and 
the copies of the forms and scientific reports sent to 
INFARMED for possible future inspections and audits

==================================================

=== CHUNK 12 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 14', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
5.2.7
other considerations
a) throughout the process, the sponsor of the material will be responsible for
undertaking the necessary follow-up to obtain all signatures in the virtual 
material review tool, as well as for obtaining the documentation that must be 
submitted to cam / infarmed, all before distribution; or, where appropriate, 
informing the departments involved in the approval process that the material 
will not be distributed.
b) an original copy of each authorized material (final version) must be kept by the 
sponsor of the material for six years from the time they were last used.
c) the tool will archive all authorized materials (final version) together with a 
copy of the forms and scientific reports sent to cam (in the case of 
promotional materials).
d) to ensure that the information is up to date, all previously prepared material to 
be reused or reprinted must undergo the approval procedure again.
e) support files generated by any of the roles involved in reviewing a material 
must include the code and the name of the corresponding material.
f)
the sponsor of the material will be responsible for destroying the promotional 
material when they consider that it is no longer suitable for promotion 
according to the this procedure and whenever a label update is approved
promotional materials | changes in smpc (new version) hardcopy and digital 
or any update of the content of the material:
to provide to the health care professionals with the most updated promotional material.
grünenthal cluster should use the most up to date promotional materials for medicinal
product with smpc). adequate steps are taken to ensure that relevant information 
about changes in the smpc related to safety issues included in the promotional 
material is communicated quickly to the appropriate members and all measures are 
taken in the appropriate time.

regulatory affairs sends to the marketing, the drug safety and medical team; 
the new smpc, smpc version and limit date to implement the changes in the 
promo materials and destruction or invalidation of the materials using previous 
versions of the product information. when the label change in the smpc is 
classified as a safety change label change category 1 or label change category 
2 the time to implement is more restrictive and can never exceed the time 
defined to implement according to proc 004879 and indicated by immediate 
and 60d respectively (for promotional material 60 d to implement instead of 90 
is feasible but shall never be more than 90 d. drug safety shall inform the 
sponsor of the material, as these categories meant a risk, and all the 
promotional materials affected shall be destroyed or updated and affect to 
promotional activities.

the marketing team sends an email to sales team informing the code of which
materials will be removed from the circulation and the limit date to run off this
materials (maximum of 6 month after the new smpc for label change category 
3-4 when applicable, that means when the sponsor of the material considers 
that an update is needed but not more than one cycle as every new cycle the

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 14.
5.2.7
Other considerations
a) Throughout the process, the sponsor of the material will be responsible for
undertaking the necessary follow-up to obtain all signatures in the virtual 
material review tool, as well as for obtaining the documentation that must be 
submitted to CAM / INFARMED, all before distribution; or, where appropriate, 
informing the departments involved in the approval process that the material 
will not be distributed.
b) An original copy of each authorized material (final version) must be kept by the 
sponsor of the material for six years from the time they were last used.
c) The tool will archive all authorized materials (final version) together with a 
copy of the forms and Scientific Reports sent to CAM (in the case of 
promotional materials).
d) To ensure that the information is up to date, all previously prepared material to 
be reused or reprinted must undergo the approval procedure again.
e) Support files generated by any of the roles involved in reviewing a material 
must include the code and the name of the corresponding material.
f)
The sponsor of the material will be responsible for destroying the promotional 
material when they consider that it is no longer suitable for promotion 
according to the this procedure and whenever a label update is approved
Promotional Materials | Changes in SmPC (new version) hardcopy and digital 
or any update of the content of the material:
To provide to the health care professionals with the most updated promotional material.
Grünenthal cluster should use the most up to date promotional materials for medicinal
product with SmPC). Adequate steps are taken to ensure that relevant information 
about changes in the SmPC related to safety issues included in the promotional 
material is communicated quickly to the appropriate members and all measures are 
taken in the appropriate time.

Regulatory Affairs sends to the Marketing, the Drug Safety and Medical team; 
the new SmPC, SmPC version and limit date to implement the changes in the 
promo materials and destruction or invalidation of the materials using previous 
versions of the product information. When the label change in the SmPC is 
classified as a safety change label change category 1 or Label change category 
2 the time to implement is more restrictive and can never exceed the time 
defined to implement according to PROC 004879 and indicated by immediate 
and 60d respectively (for promotional material 60 d to implement instead of 90 
is feasible but shall never be more than 90 d. Drug Safety shall inform the 
sponsor of the material, as these categories meant a risk, and all the 
promotional materials affected shall be destroyed or updated and affect to 
promotional activities.

The Marketing team sends an email to Sales team informing the code of which
materials will be removed from the circulation and the limit date to run off this
materials (maximum of 6 month after the new SmPC for label change category 
3-4 when applicable, that means when the sponsor of the material considers 
that an update is needed but not more than one cycle as every new cycle the

==================================================

=== CHUNK 13 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 15', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
material is reviewed and updated. for digital promotional material shall be 
updated when the information is received and the users shall refresh their digital 
material with the new smpc version.

15 days before the end date, the marketing team will resend the email to the 
sales team and inform that they need to send the promotional materials to the 
logistics company to be destroyed.

marketing team informs the procurement department of what needs to be 
destroyed by the logistics company, sending the material code (materials that 
are on the grt stock + materials that are on the sales reps stock and the 
materials sent by the sales reps).

procurement department sends an email to the asset lead / brand manager / 
product manager/ market access specialist confirming the material destruction. 
for label change category 1, 2 drug safety must be informed that the process 
has been completed according to the timelines.

when the update of the smpc is under the responsibility of a third company (in 
license agreement), the dsa and the procedure of the third company will be 
followed. in case the company does not have any procedure, grt procedures 
shall be followed
6
references
royal decree 1/ july, article 78.

last approved version of the code of good practices for the promotion of
medicines and interactions between the pharmaceutical industry and medical
professionals.

regulation applicable to self-regulatory bodies in the pharmaceutical industry.

the grünenthal group code of conduct.

regulations in force in spain and those of the autonomous community of
madrid.

memo of 21 may 2013 (muh, 8/2013): information about medicines subject to
additional monitoring. (black inverted triangle).

estatuto do medicamento (decree-law nº 20/2013, 14th of february)

publicity code (decree-law nº 330/90, 23rd of october)

regulation nº 655/2013 from the commission
7

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 15.
material is reviewed and updated. For Digital promotional material shall be 
updated when the information is received and the users shall refresh their digital 
material with the new SmPC version.

15 days before the end date, the Marketing Team will resend the email to the 
Sales team and inform that they need to send the promotional materials to the 
logistics company to be destroyed.

Marketing Team informs the Procurement Department of what needs to be 
destroyed by the logistics company, sending the material code (materials that 
are on the GRT stock + materials that are on the Sales REPs stock and the 
materials sent by the Sales REPs).

Procurement Department sends an email to the Asset Lead / Brand Manager / 
Product Manager/ Market Access Specialist confirming the material destruction. 
For label change category 1, 2 Drug Safety must be informed that the process 
has been completed according to the timelines.

When the update of the SmPC is under the responsibility of a third company (in 
license agreement), the DSA and the procedure of the third company will be 
followed. In case the company does not have any procedure, GRT procedures 
shall be followed
6
REFERENCES
Royal Decree 1/ July, Article 78.

Last approved version of the Code of Good Practices for the Promotion of
Medicines and Interactions Between the Pharmaceutical Industry and Medical
Professionals.

Regulation applicable to self-regulatory bodies in the pharmaceutical industry.

The Grünenthal Group Code of Conduct.

Regulations in force in Spain and those of the Autonomous Community of
Madrid.

Memo of 21 May 2013 (MUH, 8/2013): Information about medicines subject to
additional monitoring. (black inverted triangle).

Estatuto do Medicamento (Decree-Law nº 20/2013, 14th of February)

Publicity Code (Decree-Law nº 330/90, 23rd of October)

Regulation nº 655/2013 from the Commission
7

==================================================

=== CHUNK 14 ===
[METADATA]: {'file_name': 'GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf', 'page_label': 'Page 16', 'sop_title': 'GRT PROC English stamped Rev07 (1).docxNov302025024526'}

[CONTENT - LOWERCASE]:
revision no.
description of changes
01
this proc replaces proc-002292 (spain) and proc- 003230 
( portugal), to have a common approach for the iberia cluster.

[CONTENT - ORIGINAL]:
Source: GRT_PROC_English_stamped_Rev07 (1).docxNov302025024526.pdf, Page 16.
Revision no.
Description of changes
01
This PROC replaces PROC-002292 (Spain) and PROC- 003230 
( Portugal), to have a common approach for the Iberia Cluster.

==================================================

